{"id":46712,"date":"2022-07-28T23:02:10","date_gmt":"2022-07-28T21:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/"},"modified":"2022-07-28T23:02:10","modified_gmt":"2022-07-28T21:02:10","slug":"babylons-ask-the-ceo-series-continues-on-august-11","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/","title":{"rendered":"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11"},"content":{"rendered":"
\n

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon (NYSE:BBLN) <\/b>today announced it will host its third \u2018Ask The CEO\u2019 webcast featuring Dr. Ali Parsa, the Founder and CEO of Babylon, on August 11 at 1:00 pm EST (10:00 am PST), following the announcement of its second quarter 2022 financial results on August 9.\n<\/p>\n

<\/a><\/p>\n

\nThe \u2018Ask the CEO\u2019 series, which kicked off on May 26, features sit-down fireside chats with Dr. Parsa to answer questions from the investor community. Dr. Parsa will often be accompanied by other key company executives and stakeholders.\n<\/p>\n

\nTo attend the event, please go to the \u201cEvents\u201d page of the Investors section of the Company\u2019s website. A link to the live video webcast will also be available on this page, and a replay of the webcast will be available the day following the events. If you would like to submit a question for Dr. Parsa, please send it via email to investors@babylonhealth.com<\/a> either in advance or during the call. For more information, please visit https:\/\/ir.babylonhealth.com\/<\/a>.\n<\/p>\n

\nAbout Babylon<\/b>\n<\/p>\n

\nBabylon is one of the world\u2019s fastest growing digital healthcare companies whose mission is to make high-quality healthcare accessible and affordable for every person on Earth.\n<\/p>\n

\nBabylon is re-engineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, it offers millions of people globally ongoing, always-on care. Babylon has already shown that in environments as diverse as the developed UK or developing Rwanda, urban New York or rural Missouri, for people of all ages, it is possible to achieve its mission by leveraging its highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare.\n<\/p>\n

\nFounded in 2013, Babylon\u2019s technology and clinical services is supporting a global patient network across 15 countries, and is capable of operating in 16 languages. And through a combination of its value-based care model, Babylon 360, and its work in primary care through NHS GP at Hand, Babylon managed over 440k lives globally from the start of 2022. In 2021 alone, Babylon helped a patient every 6 seconds, with approximately 5.2 million consultations and AI interactions. Importantly, this was achieved with a 93% user retention rate in our NHS GP at Hand service and 4 or 5 star ratings from more than 90% of our users across all of our geographies.\n<\/p>\n

\nBabylon is also working with governments, health providers, employers and insurers across the globe to provide them with a new infrastructure that any partner can use to deliver high-quality healthcare with lower costs and better outcomes. For more information, please visit www.babylonhealth.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
press@babylonhealth.com<\/a>\n<\/p>\n

\nInvestors
\n
investors@babylonhealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon (NYSE:BBLN) today announced it will host its third \u2018Ask The CEO\u2019 webcast featuring Dr. Ali Parsa, the Founder and CEO of Babylon, on August 11 at 1:00 pm EST (10:00 am PST), following the announcement of its second quarter 2022 financial results on August 9. The \u2018Ask the CEO\u2019 series, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46712","6":"format-standard","7":"category-industry"},"yoast_head":"\nBabylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon (NYSE:BBLN) today announced it will host its third \u2018Ask The CEO\u2019 webcast featuring Dr. Ali Parsa, the Founder and CEO of Babylon, on August 11 at 1:00 pm EST (10:00 am PST), following the announcement of its second quarter 2022 financial results on August 9. The \u2018Ask the CEO\u2019 series, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T21:02:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220728005756\/en\/1528213\/21\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11\",\"datePublished\":\"2022-07-28T21:02:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/\"},\"wordCount\":454,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005756\\\/en\\\/1528213\\\/21\\\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/\",\"name\":\"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005756\\\/en\\\/1528213\\\/21\\\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg\",\"datePublished\":\"2022-07-28T21:02:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005756\\\/en\\\/1528213\\\/21\\\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005756\\\/en\\\/1528213\\\/21\\\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylons-ask-the-ceo-series-continues-on-august-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/","og_locale":"en_US","og_type":"article","og_title":"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11 - Pharma Trend","og_description":"AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon (NYSE:BBLN) today announced it will host its third \u2018Ask The CEO\u2019 webcast featuring Dr. Ali Parsa, the Founder and CEO of Babylon, on August 11 at 1:00 pm EST (10:00 am PST), following the announcement of its second quarter 2022 financial results on August 9. The \u2018Ask the CEO\u2019 series, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-28T21:02:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220728005756\/en\/1528213\/21\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11","datePublished":"2022-07-28T21:02:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/"},"wordCount":454,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220728005756\/en\/1528213\/21\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/","url":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/","name":"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220728005756\/en\/1528213\/21\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg","datePublished":"2022-07-28T21:02:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220728005756\/en\/1528213\/21\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220728005756\/en\/1528213\/21\/BLYN_GBL_BRD_Horizontal_Logo_White_1920x1080_JUL20.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/babylons-ask-the-ceo-series-continues-on-august-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Babylon\u2019s \u2018Ask The CEO\u2019 Series Continues on August 11"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46712"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46712\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}